Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)165.69K
Market Cap
$73.77M
Enterprise Value$85.42M
Total Cash (Recent Filing)$2.26M
Total Debt (Recent Filing)$10.94M
Price to Earnings (P/E)―
Beta0.37
Next Earnings
Nov 13, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding107,595,420
10 Day Avg. Volume209,336
30 Day Avg. Volume165,686
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue64.75
Enterprise Value/Gross Profit64.75
Enterprise Value/Ebitda-3.98
Forecast
1Y Price Target
$2.00Price Target Upside203.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Licensing AgreementsThe company's goal is to sign multiple human licensing deals, aiming for structures that include upfront payments, milestone payments, and ongoing revenue streams.
Monetization StrategyVolitionRx is working to monetize its unique nucleosomic testing assets, which could lead to significant financial gains.
Revenue GrowthRevenue grew 44% in 1Q25; licensing deals expected in 2H25.
Bears Say
Capital NeedsThe company may need to raise additional capital in the near term if sufficient cash is not received from the upcoming licensing deal.
Market TrustThe market is discounting the likelihood in human health despite management statements related to ongoing discussions with potential partners and favorable clinical data in multiple indications.
Risk FactorsRisks include, but are not limited to: failure in clinical development of diagnostic products; failure to secure license agreements for diagnostic products; failure to achieve market traction with diagnostic products; dilution risk; and going concern risk and delisting risk.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.40 and its highest was $0.94 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $73.77M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Nov 13, 2025 which is in 78 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Aug 14, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.054 by -$0.006.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.04.
How many shares outstanding does VolitionRX have?
VolitionRX has 107,595,420 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.054. Following the earnings report the stock price went up 7.812%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
VolitionRX Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (203.03% Upside)
$2.00 (203.03% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $117.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 15.0%
Last 30 Days ▲ 15.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.35%
12-Months-Change
Fundamentals
Return on Equity
138.92%
Trailing 12-Months
Asset Growth
-33.39%
Trailing 12-Months
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in cost reduction, revenue increase, and new product sales, alongside promising clinical study results. There was also strong progress in licensing and partnerships. However, concerns about uncertain revenue projections and decreasing cash reserves were noted.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$2.00
▲(203.03% Upside)
Technical Analysis
Enzo Biochem
―
BioNano Genomics
―
Burning Rock Biotech
―
Biodesix
―
bioAffinity Technologies, Inc.
―
Ownership Overview
12.26% Insiders
1.29% Mutual Funds
19.63% Other Institutional Investors
65.79% Public Companies and
Individual Investors